Boston Metal Closes $262M Series C Funding Round to Decarbonize Steelmaking and Disrupt the Metals Industry
6.9.2023 16:00:00 EEST | Business Wire | Press release
Boston Metal, a global metals technology solutions company, today announced the close of its Series C fundraising, bringing the series total to $262 million. New investors include Aramco Ventures, the corporate venturing arm of Aramco; global investment manager M&G Investments; natural resource investment firm Goehring & Rozencwajg; and investment management firm Baillie Gifford. Existing investor Breakthrough Energy Ventures also joined the round, and several others made additional investments in the Series C, including Microsoft’s Climate Innovation Fund, BHP Ventures and Prelude Ventures.
Building on the momentum of initial Series C funding announced earlier this year – which welcomed ArcelorMittal S.A., Microsoft's Climate Innovation Fund, SiteGround Capital and IFC, the private sector arm of the World Bank, as investors – Boston Metal will accelerate deployment of its high-value metals business, grow its team globally and commercially demonstrate its Molten Oxide Electrolysis (MOE) platform for decarbonized steelmaking.
“Boston Metal has made remarkable progress on the maturation of its MOE technology and business model, which has the potential to decarbonize steelmaking at scale while delivering significant value and sustainability benefits for the metals industry,” said Carmichael Roberts, Breakthrough Energy Ventures. “We’re proud to continue our investment in the company, as it’s an example of the high-impact technology we seek to support solving the world’s most pressing climate problems.”
“This investment in Boston Metal will help foster the innovation and collaboration required to address climate challenges. Green steel solutions, like Boston Metal’s, have the potential to tackle emissions in one of the most difficult-to-abate industries, and we believe the company has the leadership, technology and strategy necessary to meet this opportunity,” said Jim Sledzik, managing director, North America, Aramco Ventures.
“Boston Metal is working to decarbonize the steelmaking and metals industries,” said Thierry Masson, head of Catalyst – Americas at M&G Investments. “Boston Metal’s MOE technology paired with an experienced leadership team provides a major opportunity to reduce emissions in hard-to-abate industries worldwide. This is a good example of a climate tech company that has the potential to contribute to us living in a more sustainable world.”
The metals and mining sectors are under significant pressure to shift to more sustainable production methods while enhancing efficiency and profitability. Boston Metal is developing a scalable technology platform that uses electricity to produce a variety of metals and alloys from a wide range of feedstocks. The company’s Molten Oxide Electrolysis process is simpler, more energy efficient and has a lower environmental impact than traditional methods. With its high-value metals business, Boston Metal is empowering mining companies to create new revenue streams by deploying MOE to extract high-value metals from complex, low-concentration materials that are currently considered waste. The company’s technology for low-carbon emissions steel uses the MOE process and renewable electricity to eliminate Scope 1 and 2 carbon emissions from steelmaking, which today accounts for approximately 10% of global CO2 emissions. While many green steel solutions are dependent on scarce high-grade iron ores, the MOE technology can produce high-quality liquid steel from the more abundant medium- and low-grade iron ores.
“Boston Metal’s success in raising capital from diverse sources spanning private equity, venture capital, institutional investors and strategic investors demonstrates robust confidence in Boston Metal’s ability to transform steel and metals production for a sustainable future,” said Tadeu Carneiro, chairman and CEO, Boston Metal. “Our high-value metals business is nearing commercialization at our subsidiary in Brazil, with our manufacturing facility opening this fall, and we continue to make significant progress on the scale-up of MOE for green steel production at our pilot plant outside of Boston.”
Boston Metal is on track to ship its first high-value metals in 2024 and expects to bring MOE to the steel market by 2026, helping the industry to achieve 2050 net-zero commitments.
About Boston Metal
Boston Metal is commercializing Molten Oxide Electrolysis (MOE), a tonnage metals technology platform powered by electricity, to decarbonize steelmaking and transform how metals are made. MOE provides the metals industry with a scalable, cost-competitive and green solution for the production of steel and high-value metals from a variety of feedstocks and iron ore grades. Backed by visionary investors and led by a world-class team, Boston Metal is headquartered in Woburn, Massachusetts and has a wholly owned subsidiary in Brazil. Learn more at www.bostonmetal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905925429/en/
Contact information
Media
Annika Harper
Antenna Group for Boston Metal
bostonmetal@antennagroup.com
For Media Inquiries in Brazil
J.D. Vital
jvital@bostonmetal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 10:30:00 EET | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information and to view the Company’s abstract, visit the AACR Annual Meeting website. About ASTX295 ASTX295 is a potent, highly selective, potentially best-in-class MDM2 antagonist that has completed a phase I study (NCT03975387) in over 100 patients with advanced solid tumors. Rationally designed to exhibit a
Vonage and ServiceNow Expand their Partnership24.3.2026 10:20:00 EET | Press release
Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vonage integration, calls can automatically trigger incident categorisation, initiate ServiceNow Flow Designer subflows, and update issue resolution data in real time, helping to reduce ma
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 10:00:00 EET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 08:00:00 EET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 27-31 in Denver, Colorado. Twenty-two abstracts will be presented, including late-breaking data and three oral presentations spanning Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare. “Galderma is on a path towards becoming the undisputed dermatology powerhouse and, as such, aims to set the bar for scientific excellence in the field. The range of data we are presenting at AAD shows the strength of our commitment to this across every part of our portfolio. Patients deserve sophisticated, effective solutions that meet their diverse and evolving needs, and our science is built to deliver exactly that.” BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D AND CORPORATE DEVELOPMENT GALDERMA Therapeutic Dermatology: Latest updat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
